Publications

View the most recent publications in which DGr Pharma is involved…

• Bradykinin Challenge Provides Surrogate Endpoints For Hereditary Angioedema TreatmentUsing Bradykinin-B2-Receptor Antagonists
• PHA-022121, a Selective Bradykinin-B2-Receptor Antagonist, Is Safe and Shows Rapid Oral Bioavailability in Humans